Petrylak, D.
162  Ergebnisse:
Personensuche X
?
1

Predictive biomarkers for survival benefit with ramucirumab..:

van der Heijden, MS ; Powles, T ; Petrylak, D...
https://eprints.whiterose.ac.uk/186635/1/Predictive%20biomarkers%20for%20survival%20benefit%20with%20ramucirumab%20in%20urothelial%20cancer%20in%20the%20RANGE%20trial.pdf.  , 2022
 
?
 
?
3

ARCHES: Efficacy of androgen deprivation therapy (ADT) with..:

A. Stenzl ; R.Z. Szmulewitz ; D. Petrylak...
http://www.sciencedirect.com/science/article/pii/S2666168320331608.  , 2020
 
?
4

Role of Genetic Testing for Inherited Prostate Cancer Risk:..:

Giri, VN ; Knudsen, KE ; Kelly, WK...
Giri , VN , Knudsen , KE , Kelly , WK , Abida , W , Andriole , GL , Bangma , C H , Bekelman , JE , Benson , MC , Blanco , A , Burnett , A , Catalona , WJ , Cooney , KA , Cooperberg , M , Crawford , DE , Den , RB , Dicker , AP , Eggener , S , Fleshner , N , Freedman , ML , Hamdy , FC , Hoffman-Censits , J , Hurwitz , MD , Hyatt , C , Isaacs , WB , Kane , CJ , Kantoff , P , Karnes , RJ , Karsh , LI , Klein , EA , Lin , DW , Loughlin , KR , Lu-Yao , G , Malkowicz , SB , Mann , MJ , Mark , JR , McCue , PA , Miner , MM , Morgan , T , Moul , JW , Myers , RE , Nielsen , SM , Obeid , E , Pavlovich , CP , Peiper , SC , Penson , DF , Petrylak , D , Pettaway , CA , Pilarski , R , Pinto , PA , Poage , W , Raj , GV , Rebbeck , TR , Robson , ME , Rosenberg , MT , Sandler , H , Sartor , O , Schaeffer , E , Schwartz , GF , Shahin , MS , Shore , ND , Shuch , B , Soule , HR , Tomlins , SA , Trabulsi , EJ , Uzzo , R , Griend , DJV , Walsh , PC , Weil , CJ , Wender , R & Gomella , LG 2018....  , 2018
 
?
5

Impact of prognostic factors and risk groups on overall sur..:

Bellmunt, J ; de Wit, R ; Vaughn, D. J...
Bellmunt , J , de Wit , R , Vaughn , D J , Fradet , Y , Lee , J L , Fong , L , Vogelzang , N J , Climent , M A , Petrylak , D , Choueiri , T K , Necchi , A , Gerritsen , W R , Gurney , H , Quinn , D I , Culine , S , Sternberg , C N , Jensen , E , Frenkl , T , Perini , R F & Bajorin , D 2018 , ' Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC) : post hoc analysis of KEYNOTE-045 ' , Annals of Oncology , vol. 29 , no. Supplement 8 , pp. viii320-viii321 . https://doi.org/10.1093/annonc/mdy283.110.  , 2018
 
?
 
?
10

Clinical Outcomes in Men of Diverse Ethnic Backgrounds with..:

Halabi, S ; Dutta, S ; Tangen, C.M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580036/.  , 2020
 
?
13

Health-related quality of life in the randomized phase 3 st..:

Necchi, A ; Nishiyama, H ; Matsubara, N...
Necchi , A , Nishiyama , H , Matsubara , N , Lee , JL , Petrylak , DP , de Wit , R , Drakaki , A , Liepa , AM , Mao , HZ , Bell-McGuinn , K & Powles , T 2020 , ' Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE) ' , BMC Urology , vol. 20 , no. 1 , 181 . https://doi.org/10.1186/s12894-020-00752-w.  , 2020
 
?
15

Randomized phase III KEYNOTE-045 trial of pembrolizumab ver..:

Fradet, Y ; Bellmunt, J ; Vaughn, D. J...
Fradet , Y , Bellmunt , J , Vaughn , D J , Lee , J L , Fong , L , Vogelzang , N J , Climent , M A , Petrylak , D P , Choueiri , T K , Necchi , A , Gerritsen , W , Gurney , H , Quinn , D I , Culine , S , Sternberg , C N , Nam , K , Frenkl , T L , Perini , R F , De Wit , R & Bajorin , D F 2019 , ' Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer : results of >2 years of follow-up ' , Annals of Oncology , vol. 30 , no. 6 , mdz127 , pp. 970-976 . https://doi.org/10.1093/annonc/mdz127.  , 2019
 
1-15